283 related articles for article (PubMed ID: 15788682)
41. PHA665752 inhibits the HGF-stimulated migration and invasion of cells by blocking PI3K/AKT pathway in uveal melanoma.
Wang Z; He C; Liu L; Ma N; Chen X; Zheng D; Qiu GH
Neoplasma; 2017; 64(3):377-388. PubMed ID: 28253717
[TBL] [Abstract][Full Text] [Related]
42. MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks.
Medová M; Aebersold DM; Zimmer Y
Int J Cancer; 2012 Feb; 130(3):728-34. PubMed ID: 21400509
[TBL] [Abstract][Full Text] [Related]
43. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
[TBL] [Abstract][Full Text] [Related]
44. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
[TBL] [Abstract][Full Text] [Related]
45. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
[TBL] [Abstract][Full Text] [Related]
46. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.
Mondesire WH; Jian W; Zhang H; Ensor J; Hung MC; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2004 Oct; 10(20):7031-42. PubMed ID: 15501983
[TBL] [Abstract][Full Text] [Related]
47. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
[TBL] [Abstract][Full Text] [Related]
48. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
49. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Milazzo M; Chieco P; Negrini M; Calin GA; Grazi GL; Pollutri D; Croce CM; Bolondi L; Gramantieri L
Cancer Res; 2010 Jun; 70(12):5184-93. PubMed ID: 20501828
[TBL] [Abstract][Full Text] [Related]
50. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.
Mauceri HJ; Sutton HG; Darga TE; Kocherginsky M; Kochanski J; Weichselbaum RR; Vokes EE
Oncol Rep; 2012 May; 27(5):1625-9. PubMed ID: 22294050
[TBL] [Abstract][Full Text] [Related]
51. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.
Lau PC; Wong EY
Pathol Oncol Res; 2012 Apr; 18(2):357-63. PubMed ID: 21866424
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
53. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.
Zimmer Y; Vaseva AV; Medová M; Streit B; Blank-Liss W; Greiner RH; Schiering N; Aebersold DM
Cancer Lett; 2010 Mar; 289(2):228-36. PubMed ID: 19783361
[TBL] [Abstract][Full Text] [Related]
54. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells.
Cerovac V; Monteserin-Garcia J; Rubinfeld H; Buchfelder M; Losa M; Florio T; Paez-Pereda M; Stalla GK; Theodoropoulou M
Cancer Res; 2010 Jan; 70(2):666-74. PubMed ID: 20068168
[TBL] [Abstract][Full Text] [Related]
55. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi Y; Frankel A; Radvanyi LG; Penn LZ; Miller RG; Mills GB
Cancer Res; 1995 May; 55(9):1982-8. PubMed ID: 7728769
[TBL] [Abstract][Full Text] [Related]
56. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
[TBL] [Abstract][Full Text] [Related]
57. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors.
Bagai R; Fan W; Ma PC
IDrugs; 2010 Jun; 13(6):404-14. PubMed ID: 20506063
[TBL] [Abstract][Full Text] [Related]
58. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin.
Wu MJ; Chang CH; Chiu YT; Wen MC; Shu KH; Li JR; Chiu KY; Chen YT
Urol Oncol; 2012; 30(1):69-77. PubMed ID: 20207175
[TBL] [Abstract][Full Text] [Related]
59. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
[TBL] [Abstract][Full Text] [Related]
60. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
